GSK still riding vaccine sales wave, pushing 2024 forecasts higher

GSK’s vaccines portfolio is front and center as it kicks off 2024.

The UK pharma said its non-Covid vaccine sales grew 22% in the first three months of the year to £2.27 billion ($2.83 billion) compared to the same period in 2023. This means its vaccines franchise now accounts for around 30% of total sales.

“We continued to strengthen our innovative vaccine portfolio this quarter,” CEO Emma Walmsley said on a media call. The company raised its 2024 operating profit growth guidance on Wednesday from a previous range of 7% to 10%, to 9% to 11%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Pharmalittle: We’re reading about docs paid for endorsements, Novartis suing Maryland, and lots more

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal

May 31, 2024

Physicians ask FDA to revoke approval of DNA test for opioid addiction

Dive Brief: Physicians asked the Food and Drug Administration Thursday to revoke its recent approval of Autogenomics’ AvertD genetic test for opioid addiction. The Physicians

April 8, 2024

Comparing camel, cow, and goat milk: Which is best for diabetes and heart health?

Camel milk’s nutritional profile supports diabetes and heart health, offering superior metabolic benefits over cow and goat milk for chronic disease management.

November 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.